Motilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...

Indian companies show strong recovery. Over 50 firms moved from losses to profits in the March quarter. This turnaround happened despite ma...

Brokerages maintain a positive outlook on select large-cap pharmaceutical, automobile, and healthcare stocks, citing strong growth prospect...

Indian equity benchmarks closed modestly higher on Friday, with financial stocks leading the gains. The Nifty and Sensex edged up, though p...

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...

Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formul...

Sun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...

Brokerages remain selective, with Motilal Oswal maintaining a bullish stance on UTI AMC and Aditya Birla Sun Life AMC, citing steady AUM gr...

Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & ...

Indian drug maker Sun Pharma faces significant exposure to potential US tariffs on medicines. Global brokerage Jefferies warns that while g...

Sun Pharma share price: Sun Pharmaceutical's shares declined following a reported 20% YoY drop in Q1FY26 net profit, despite a 10% increase...

Motilal Oswal has raised target price to Rs 900 and maintained a ‘buy’ rating on the back of improving traction in specialty products. Edel...

CLSA upgraded the target price of the stock to Rs 540 from Rs 520 earlier.

Taro Pharma reported a 422 per cent year-on-year (YoY) jump in its net profit for the third quarter.

The drug in question is CEQUA (cyclosporine ophthalmic solution) 0.09 per cent.

The USFDA’s Establishment Inspection Report (EIR) comes days after the company received Voluntary Action Indicated (VAI) that indicated tha...

The move had not gone down well with few brokerage houses who had raised concerns over the company investing in an unrelated business area.